ISHLT Pulmonary Function Test/Spirometry and Co-Relationships with Lung Transplantation and BOS Research Grant
Supported By:
Zambon
Bronchiolitis Obliterans Syndrome (BOS) is a severe and progressive lung disease that occurs in individuals who have undergone lung transplantation. BOS is characterized by inflammation and scarring of the small airways in the lungs, leading to a decline in pulmonary function and respiratory symptoms.
Pulmonary function testing is a crucial tool for diagnosing and monitoring BOS. Specifically, spirometry and forced expiratory volume in one second (FEV1) are the most used tests to assess lung function in patients with BOS. These tests allow for the early detection of changes in lung function, which can prompt early intervention and potentially improve outcomes.
Despite the importance of pulmonary function testing in BOS, there are still significant gaps in our understanding of the disease and its relationship with lung function testing. Therefore, further research is needed to identify novel biomarkers and better understand the pathophysiology of BOS, ultimately leading to improved diagnosis, treatment, and outcomes for patients.
Purpose
The purpose of this grant is to fund research that aims to improve the understanding of the relationship between pulmonary function testing, lung transplantation, and the development and progression of BOS (If PFT measure can become predictor for the BOS development). Specifically, this grant will support research projects that focus on identifying novel ways for early detection and monitoring of BOS using pulmonary function testing, investigating the pathophysiology of BOS and its impact on lung function, and identifying trajectories of lung function decline in patients with BOS over time.
This research will aim to fill significant gaps in our understanding of BOS and pulmonary function testing, and its relationship, ultimately leading to improved diagnosis, treatment, and possibly survival outcomes for patients with BOS.
Grant Details
One grant of up to $20,000 will be awarded for one year.
- The applicant must have an academic or clinical appointment or may be in training at an accredited institution.
- A letter of institutional commitment from a division or department chair at the institution at which the research will be conducted must be provided.
- The applicant must be an active member of ISHLT or have submitted a completed membership application by 29 September. If selected to receive the grant, the awardee must remain a member of ISHLT for the duration of the funding.
- There are no restrictions on past or current funding.
- The applicant may be a past or current recipient of ISHLT funding including Fellowship or Faculty Development research grants.
- The applicant may currently hold career development awards, mentoring awards, or other independent research awards.
- If the applicant is currently receiving funding for a project similar to the topics described in this request for applications, the applicant should explain how the funds of the grant would not overlap with the funds of the other research support.
- Applicants who have a substantial relationship with Zambon that would present a real or perceived conflict of interest if awarded this grant must first contact ISHLT to declare the conflict before submitting an application. Examples of a substantial
relationship with an industry partner include: board member, member of advisory council, consultant, lecturer, et
- Employees of Zambon cannot submit an application.
- Upon disclosure, the Grants and Awards Committee will determine if the individual is eligible to submit an application and will notify the individual in a timely manner.
Please review these guidelines and terms prior to completing your application. If you are ultimately awarded a grant, you will sign a letter of agreement (LOA) stating that you agree to these funding guidelines and terms, and the LOA will be co-signed by your institution’s grants/research office.
- Research is anticipated to begin between January and December of the grant year.
- Funding in the amount of $20,000 will be provided for the research project.
- Funding will not be released until visa status is confirmed (if applicable).
- The grant is intended to provide salary support for the researcher, other study personnel, statistical support, supplies/materials, animals, publication costs and travel related costs for abstract presentation and up to 10 percent of the grant can be used for institutional overhead. No other costs are permitted.
- The grant will be paid in multiple installments to the recipient’s institution. First installment (50% of funds) will be paid at the beginning of grant work; the second installment (25%) will be paid mid-award (after receipt of a grant progress report) and the final installment (25%) will be paid after receipt of a final report.
- Grant funding is generally not transferable from one recipient to another; transfer may be considered under compelling circumstances (e.g., the grantee leaves the institution and does not request a transfer of the grant, or the grantee requires an extended medical leave).
- If the grantee relocates and requests to move the grant to the new institution, the Grants and Awards Committee will determine if the grant can be transferred to the recipient’s new location, or if the grant must be surrendered and any remaining funds returned. If the grant is surrendered, a final report will still be required.
- If the grantee relocates and does not request a transfer of the grant to the new institution, the current institution (i.e., department chair or division chair and Office of Sponsored Research) may select a new PI. The Grants and Awards Committee will determine if the grant can be continued at the current institution.
- The applicant must acknowledge the grant as a funding source in all manuscripts and presentations derived from the funded research using the following statement: “This work was supported by a grant from Zambon and the International Society for Heart and Lung Transplantation.” Copies of such publications must be submitted to ISHLT.
- Pursuant to regulations of the federal Physician Payment Sunshine Act (included in the Affordable Care Act), NPI numbers will be collected from grant recipients (if applicable), and tax ID numbers collected from the recipients’ institutions (if applicable). All payments will be reported to the Centers for Medicare and Medicaid Services Open Payments system, as payments from ISHLT represent indirect transfers of value from the funding pharmaceutical company.
- Reports are required at the following intervals depending on the term of the grant, and continuation of funding is contingent upon completion of these reports:
- Mid-award progress report due six months after research start date.
- Final report within 30 days of the conclusion of the grant term.
- A final report is required even if the grant is surrendered for any reason prior to the conclusion of the grant term.
- Selection of the grant recipient will be made by an expert review committee. The Grant and Awards Committee will work with the Interdisciplinary Networks and Professional Committees to identify the experts that will review the applications. Representatives from Zambon cannot be part of the review committee. In case of a very close or tie score, the ISHLT Grants and Awards Committee will make the final decision. Consultation from expert reviewer(s) may be requested.
- Grants will be scored on factors including but not limited to study aims, significance, innovation, research approach, feasibility of obtaining relevant data, and prior work, as well as other factors.
- All applicants will be notified as to whether or not they have been selected to receive the research grant by 15 November.
- For the individual selected, the term of the grant will be one year beginning between January – December of the grant year.
